Chronic Lymphocytic Leukaemia (CLL) is a type of slow developing type of white blood cell cancer. It is most common in those above 60 years old and rarely occurs in people below 40 years old. Some people with CLL have genetic changes in a gene (TP53) which is responsible for production of Tumour Protein 53; a protein which suppresses cancer. CLL patients with genetic changes to the TP53 gene have shorter survival times and often don’t respond to existing treatments options.The GIVe chemotherapy regime involves giving CLL patients 3 different chemotherapy drugs (Ibrutinib, Venetoclax and Obinutuzumab) together as part of a six month treatment programme. Each of these drugs is licensed and given individually to treat CLL, however to date they have not been used in combination. If the GIVe chemotherapy regime was licenced in the UK it could provide a new treatment option to CLL patients with genetic TP53 changes. This sub-group of CLL patients currently have limited treatment options.
Ibrutinib with Venetoclax and Obinutuzumab for the treatment of Chronic Lymphocytic Leukaemia patients with TP53 deletion and/or mutation
Interventions: Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)
Indications: Chronic lymphocytic leukaemia (CLL)
Therapeutic Areas: Haematological Cancer and Lymphomas